Pfizer (NYSE: PFE) Stock
Pfizer Inc (NYSE: PFE) is a major biotech drug manufacturer and a Dow component. The Pfizer stock dividend strength frequently makes it a Dogs of the Dow favorite pick. Pfizer is the globe’s biggest research-based pharmaceutical company. Pfizer pharmaceuticals can be seen worldwide with approvals on all continents of the world.
The March 2009 Pfizer drug pipeline contained the following phase 3 drugs:
Zithromax/chloroquine - Infectious Diseases for malaria
CP-751871(figitumumab) - Oncology for non-small cell lung cancer
axitinib - Oncology for renal cell carcinoma
Sutent – Oncology for cancer - varity
apixaban - Cardiovascular & Metabolic Diseases for Acute Coronary Syndrome
PF-4383119 (tanezumab) - Neuroscience for Alzheimer’s Dementia
Lyrica – Neuroscience for anxiety
Celebrex – Pain for gouty arthritis
CP-690550 - Inflammation for Rheumatoid Arthritis
PF-1228305 (Thelin) - Respiratory for Pulmonary Hypertension
Eraxis/Vfend Infectious Diseases for Aspergillosis
PF-5076985 (Xiaflex) - Inflammation for Dupuytren's Contracture
dalbavancin - Infectious Diseases for Skin and Skin Structure Infections
Macugen - Ophthalmology for Diabetic Macular Edema
Pfizer stock is one of the most actively traded stocks in the world and top among biotech companies. Its common stock is traded for investors on the New York Stock Exchange (NYSE) and also on the London, Euronext, and Swiss exchanges. Pfizer is best known for its blockbuster drugs that tackle health in the areas of sexual dysfunction, allergy, cardiovascular, dermatology, and others. The company also has a strong animal medicine sector, Pfizer Animal Health, which made a major acquisition of Embrex in January 2007. Pfizer pharmaceuticals remains a strong contributor to the quality of life and life expectations in the US and abroad. The Pfizer stock has a unique name and is often misspelled with variations like Phizer, Pfeizer, Pfiser, and Pfitzer all being searched regularly in Google.
Pfizer Earnings History:
Q1 2007: up 10.3%
Q2 2007: down 23.8%
Q3 2007: up 6.9%
Q4 2007: up 17.3%
Pfizer Inc next earnings report: Q1 2008: $0.66 E
The success of Pfizer stock is largely dependent on its ability to maintain a strong drug pipeline and successfully execute on its approved drug sales objectives. The company has been an active player in the M&A realm, frequently stepping outside of itself to purchase both young and mature drug companies. Like any pharmaceutical company, Pfizer will suffer from FDA and other regulatory set backs from time to time, but investors will judge the long term potential of the company’s pipeline will drive long term returns. As mentioned, the company is heavily traded meaning the shares remain relatively stable on a day-to-day basis yielding a low Beta for the equity.
